

SPECIFICATION

Page 1, first paragraph, change the title of the invention to read:

**FORMULATION OF TOPICAL BETA BLOCKERS WITH IMPROVED EFFICACY
AND PROCESS FOR MANUFACTURING IT**

Page 1, lines 12-16 (fourth paragraph), substitute the following paragraph:

Beta-blockers are known to reduce I.O.P. mainly by reduction in aqueous secretion. This reduction in aqueous secretion is dose dependent. However, increasing the dosage beyond a point does not improve its capacity to reduce I.O.P. For timolol, levobunolol and betaxalol it is achieved at 0.5% concentration, for carteolol it is 1%, and for metipranolol it is 0.3%. Increasing concentration beyond this does not result in further reduction in I.O.P.

Page 3, lines 8-10 (fifth paragraph), substitute the following paragraph:

Beta-blockers described above can be timolol 0.5%, betaxolol 0.5%, levobunolol 0.5%, carteolol 1.0%, metipranolol 0.3%, or any other Beta-blocker which can reduce I.O.P in a therapeutic concentration.

Page 3, lines 11-12 (sixth paragraph), substitute the following paragraph:

Carbopol is a registered trademark for a family of resins which have been given the generic name "carbomer." The carbomer can be Carbopol 940, 932, 970 or others which form a gel in aqueous solution. The concentration of carbomer in the final formulation can be from 0.5% to 5%.